Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides
Per Björk(Active Biotech (Sweden)), Tomas Leanderson(Lund University), Anders Olsson(Linköping University), Thomas Vogl(University of Münster), Johannes Roth(Blackberry (United States)), Anders Björk(Active Biotech (Sweden)), Fredrik Ivars(Lund University), David Liberg(Active Biotech (Sweden)), Martin Stenström(Lund University)
Cited by 358
Related Papers
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
|New England Journal of Medicine|2012|2k
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
|The Lancet|2014|750
Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock
|Nature Immunology|2003|363
Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia
|New England Journal of Medicine|2010|334
Type I IFN Signaling Is Crucial for Host Resistance against Different Species of Pathogenic Bacteria
|The Journal of Immunology|2007|246